The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RADICAL trial: A phase Ib/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients progressing on these aromatase inhibitors (AIs).
 
Michael Seckl
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - AstraZeneca (Inst)
Expert Testimony - Teva
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Philip David Badman
No Relationships to Disclose
 
Xinxue Liu
No Relationships to Disclose
 
Iain R. MacPherson
Honoraria - Roche
Consulting or Advisory Role - Celldex; Pierre Fabre; Roche
Speakers' Bureau - Roche
Research Funding - Celldex; Merck; Novartis; Roche; Synthon; Tesaro
Travel, Accommodations, Expenses - Eisai
 
Ishtiaq Husain Zubairi
Stock and Other Ownership Interests - GlaxoSmithKline; Roche
 
Richard D. Baird
Consulting or Advisory Role - Shionogi
Research Funding - AstraZeneca (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Genentech (Inst); Molecular Partners (Inst); Roche (Inst); Sanofi (Inst); Shionogi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Molecular Partners; Shionogi
 
Javier Garcia-Corbacho
No Relationships to Disclose
 
Nicola Cresti
No Relationships to Disclose
 
Elizabeth R. Plummer
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Consulting or Advisory Role - Astex Pharmaceuticals; AstraZeneca; Bayer; Clovis Oncology; Karus Therapeutics; Mission Therapeutics; MSD Oncology; Novartis; Pierre Fabre; Roche/Genentech; Vertex
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); Eisai (Inst); Etherapeutics (Inst); Ipsen (Inst); vertex (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Anne Caroline Armstrong
Consulting or Advisory Role - Roche
 
Rozenn Allerton
Travel, Accommodations, Expenses - Roche
 
Donal Landers
Employment - AstraZeneca
 
Hanna Nicholas
No Relationships to Disclose
 
Lyndall McLellan
No Relationships to Disclose
 
Adrian K. Lim
Speakers' Bureau - Toshiba
Research Funding - Philips Healthcare; Toshiba
 
Charles Coombes
No Relationships to Disclose